|
|
|
Drug Usage Trend study
Introduction to Drug Usage Trend study:
The "Usage Trend Study" looks in to various products' awareness, usage, satisfaction, product image and future usage expectations (increase/stay the same/decrease). This study was first started in 1984 as "Drug Usage and Satisfaction Study" via postal survey, and have been conducted over 40 times. In December 2006, the study was updated to the current methodology (online).
This study currently covers 10 therapeutic areas (drug types):
- Anti-hypertensive drugs*
- Anti-hyperlipidemia drugs*
- Antibiotics*
- Anti-rheumatic arthritis drugs*
- Oral non steroid anti-inflammatory drugs; NSAIDs*
- Patch/tape non steroid anti-inflammatory drugs; NSAIDs*
- Anti-allergy drugs (from Oct. 2007)**
- BPH / urinary disorder treatment drugs (from Oct. 2007)**
- Antiplatelets (from Jan. 2008)***
- a.Osteoporosis drugs (from Jan. 2008)***
- *For the above 6 therapeutic types (a-f), past studies were conducted in Dec. 2006, Oct. 2007, May 2008, Nov. 2008.
- **For the above 2 therapeutic types (g & h), past studies were conducted in Oct. 2007, May 2008, Nov. 2008.
- ***For the above 2 therapeutic types (i & j), past studies were conducted in Jan. 2008, Aug. 2008, Feb. 2009.
- Studies for above 8 therapeutic types (a-h) are underway for May 2009.
Outline of Drug usage trend study:
- Project name: Drug usage trend study
- Objective: To quantitatively understand the awareness, usage, product image, satisfaction and future usage intensions of various products.
- Methodology: Online survey (since Dec. 2006)
- Survey region: Nationwide
- Sample size: (differs depending on therapeutic area: see below for breakdown)
| |
Hyper-tension |
Hyper-lipidemia |
Antibiotics |
Oral NSAIDs |
Patch NSAIDs |
RA |
Allergy |
BPH |
Anti-platelets |
Osteo-porosis |
| General IM |
263 |
257 |
257 |
264 |
264 |
258 |
255 |
261 |
265 |
270 |
| Gastroenterologists |
53 |
53 |
|
|
|
|
|
|
|
|
| Cardiologists |
58 |
55 |
|
|
|
|
|
|
52 |
54 |
| Endocrinologists |
55 |
58 |
|
|
|
|
|
|
|
|
| Nephrologists |
34 |
33 |
|
|
|
|
|
|
|
|
| Neurologists |
|
|
|
|
|
|
|
|
50 |
50 |
| Pulmonologists |
|
|
62 |
|
|
|
59 |
|
|
|
| Rheumatologists |
|
|
|
34 |
34 |
36 |
|
|
|
|
| Surgeons |
|
|
100 |
101 |
101 |
|
|
|
100 |
101 |
| Orthopedics |
|
|
|
102 |
102 |
102 |
|
|
98 |
101 |
| Brain surgeons |
54 |
53 |
|
|
|
|
|
|
52 |
53 |
| Dermatologists |
|
|
63 |
|
|
|
65 |
|
|
|
| ENT |
|
|
65 |
|
|
|
63 |
|
|
|
| Urologists |
|
|
104 |
|
|
|
|
104 |
|
|
| TOTAL (n=) |
517 |
509 |
651 |
501 |
501 |
396 |
442 |
365 |
617 |
629 |
*Sample from latest version (Feb. 2009 for antiplatelets and osteoporosis / Nov. 2008 version for rest)
Contents of Drug usage trend study:
For each area, the study topics include:
- Awareness and usage of specific drugs (see list below)
- Allows you to see the product's share within the therapeutic area, and also the trend by looking at the past results
- Also it covers the reasons for using each product
- Product image
- Each product is evaluated by various attributes (such as "strong efficacy" "long duration of effect" etc.) so that you can understand how products are positioned by the physicians.
- Product satisfaction
- Each product is evaluated numerically in terms of satisfaction levels (efficacy and safety).
- Future usage expectations
- Respondents are asked about their expected use of each product in 6 months time (increase, decrease, stay same, discontinue etc.).
- For products they intend to switch (use less/discontinue), they are asked to which products they will switch to (including generics), and also the reason for why they intend to switch to that drug.
Product list for each area:
Some results (from BPH study Nov 2008):
- Results showed that majority of the physicians were prescribing Harnal (tamsulosin), to their BPH patients. Harnal (tamsulosin) also had the highest prescription rates, with 36.7% of BPH patients being prescribed with this.
- In the next 6 months, approximately half the respondents using Urief (silodosin) estimated that their usage of Urief will increase. Interesting to note, approximately half of the respondents using Avishot (naftopidil) mentioned that their usage will decrease or that they will discontinue using Avishot in the next 6 months. This is most likely due to fact that the announcement of Avishot discontinuing its sales was reported during the fieldwork duration. Majority of respondents mentioned that they will most likely switch to Flivas (naftopidil) in place of Avishot.
PRICE:
Antihypertensive drugs = 750,000 YEN
All other disease topics = 500,000 YEN / per topic
- *If payment is to be made domestically, additional 5% local tax will be added to the total fee
|
 |
|
|
|
|
